Table 1 Baseline demographic and clinicopathologic findings
All patients (n = 55) | Insulin resistance | p | |||
|---|---|---|---|---|---|
Yes (n = 30) | No (n = 25) | ||||
Age (median) (min-max) | 48.5 (27–80) | 52 (29–80) | 45 (27–66) | 0.06 | |
BMI (median) (min-max) | 29.6 (18.9–43.4) | 33.25 (18.92–43.4) | 27.01 (21–35.2) | 0.01 | |
Waist circumference (cm) | 100 (56–116) | 100 (56–116) | 89 (56–106) | 0.7 | |
Hip circumference (cm) | 108 (58–134) | 110 (58–134) | 106 (95–120) | 0.5 | |
Fasting glucose level (mg/dl) | 99 (72–125) | 103 (82–125) | 91 (72–115) | 0.003 | |
HDL (mg/dl) | 57 (24–96) | 55 (24–83) | 59 (40–96) | 0.07 | |
LDL (mg/dl) | 124 (51–219) | 120 (51–198) | 139 (61–219) | 0.6 | |
Total cholesterol (mg/dl) | 215 (117–314) | 205 (117–298) | 218 (127–314) | 0.5 | |
Trigliseride (mg/dl) | 98 (56–467) | 121 (58–467) | 89 (56–164) | 0.007 | |
Metabolic syndrome | Yes | 22 (40%) | 17 (57%) | 5 (20%) | 0.006 |
No | 33 (60%) | 13 (43%) | 20 (80%) | ||
Menopause status (n) (%) | Pre-menopause | 32 (58%) | 16 (53%) | 16 (69%) | 0.4 |
Post-menopause | 23 (42%) | 14 (47%) | 9 (31%) | ||
Clinical stage | 2A | 9 (16%) | 7 (23%) | 2 (8%) | 0.2 |
2B | 18 (32%) | 10 (33%) | 8 (32%) | ||
3A | 20 (36%) | 8 (27%) | 12 (48%) | ||
3B | 7 (14%) | 5 (17%) | 2 (8%) | ||
3C | 1 (2%) | 0 (0%) | 1 (4%) | ||
Pathologic subtype | Invazive ductal | 44 (80%) | 26 (87%) | 18 (72%) | 0.8 |
Invazive lobular | 5 (9%) | 1 (3%) | 4 (16%) | ||
Others | 6 (11%) | 3 (10%) | 3 (12%) | ||
Receptor status | HR+, HER-2− | 31 (56%) | 17 (56%) | 14 (56%) | 0.7 |
HR−, HER-2+ | 7 (13%) | 5 (16%) | 2 (8%) | ||
HR+, HER-2+ | 9 (16%) | 4 (14%) | 5 (20%) | ||
HR−, HER-2− | 8 (15%) | 4 (14%) | 4 (16%) | ||
Hormone receptor status | ER + PR+ | 31 (56%) | 18 (60%) | 13 (52%) | 0.9 |
ER + PR− | 9 (16%) | 3 (10%) | 6 (24%) | ||
ER − PR+ | 0 (0%) | 0 (0%) | 0 (0%) | ||
Ki 67 index | ≤ 15 | 13 (24%) | 11 (37%) | 2 (8%) | 0.01 |
> 15 | 42 (76%) | 19 (63%) | 23 (92%) | ||
Pathological response | CR | 16 (29%) | 5 (16%) | 11 (44%) | 0.02 |
Non-CR | 39 (71%) | 25 (84%) | 14 (56%) | ||